Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer
Abstract A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Of the 40 evaluable female patients, the ORR was 62.5%. All patients have responded with one (2.5%) complete response, 24 (60%) partial response, 12 (30%) stable disease, and 3 (7.5%) progressive disease. The OS and PFS were 20 months (95% CI: 11.9–28 months) and 13 months (95% CI: 8.0–17.9 months), respectively. Survival (OS and PFS) were longer in patients with good performance status and in patients older than 65 years (P < 0.05). The most frequently observed toxicities were rash/dry skin (80%), diarrhea (42.5%), and vomiting/anorexia (32.5%). Four patients developed grade 3 toxicities (rash and diarrhea) but did not require either dose reduction or discontinuation. Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Medical oncology - 29(2011), 2 vom: 12. März, Seite 595-599 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Deng, Jing [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
doi: |
10.1007/s12032-011-9891-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR023875429 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR023875429 | ||
003 | DE-627 | ||
005 | 20230519132738.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12032-011-9891-2 |2 doi | |
035 | |a (DE-627)SPR023875429 | ||
035 | |a (SPR)s12032-011-9891-2-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.81 |2 bkl | ||
100 | 1 | |a Deng, Jing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Of the 40 evaluable female patients, the ORR was 62.5%. All patients have responded with one (2.5%) complete response, 24 (60%) partial response, 12 (30%) stable disease, and 3 (7.5%) progressive disease. The OS and PFS were 20 months (95% CI: 11.9–28 months) and 13 months (95% CI: 8.0–17.9 months), respectively. Survival (OS and PFS) were longer in patients with good performance status and in patients older than 65 years (P < 0.05). The most frequently observed toxicities were rash/dry skin (80%), diarrhea (42.5%), and vomiting/anorexia (32.5%). Four patients developed grade 3 toxicities (rash and diarrhea) but did not require either dose reduction or discontinuation. Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC. | ||
650 | 4 | |a Gefitinib |7 (dpeaa)DE-He213 | |
650 | 4 | |a Female |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pretreated |7 (dpeaa)DE-He213 | |
650 | 4 | |a Non-small-cell lung cancer |7 (dpeaa)DE-He213 | |
700 | 1 | |a Fang, Wei Jia |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Xiao Chen |e verfasserin |4 aut | |
700 | 1 | |a Wu, Dong Ping |e verfasserin |4 aut | |
700 | 1 | |a Fang, Hong Ming |e verfasserin |4 aut | |
700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
700 | 1 | |a Qian, Jiong |e verfasserin |4 aut | |
700 | 1 | |a Mou, Hai Bo |e verfasserin |4 aut | |
700 | 1 | |a Chu, Bin Bin |e verfasserin |4 aut | |
700 | 1 | |a Xu, Nong |e verfasserin |4 aut | |
700 | 1 | |a Teng, Li Song |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medical oncology |d New York, NY : Springer, 1984 |g 29(2011), 2 vom: 12. März, Seite 595-599 |w (DE-627)SPR023865016 |w (DE-600)2008172-8 |x 1559-131X |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2011 |g number:2 |g day:12 |g month:03 |g pages:595-599 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12032-011-9891-2 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.81 |q ASE |
951 | |a AR | ||
952 | |d 29 |j 2011 |e 2 |b 12 |c 03 |h 595-599 |